Trade EyePoint Pharmaceuticals, Inc. - EYPT CFD

EyePoint Pharmaceuticals, Inc. Company profile

About Eyepoint Pharmaceuticals Inc

EyePoint Pharmaceuticals, Inc. is a pharmaceutical company that is focused on developing and commercializing therapeutics to help improve eye disorders. The Company's products include EYP-1901, YUTIQ50, DEXYCU and YUTIQ. EYP-1901, which combines a bioerodible formulation of its proprietary Durasert sustained-release technology with vorolanib, a tyrosine kinase inhibitor. EYP-1901 is in Phase I clinical trial and targeting treatment of wet age-related macular degeneration for additional indications in diabetic retinopathy and retinal vein occlusion. DEXYCU is a single-dose treatment for postoperative inflammation following ocular surgery. YUTIQ50 is a potential twice-yearly treatment for non-infectious uveitis affecting the posterior segment of the eye. YUTIQ is a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. It is utilizing its core technology platform, Durasert to deliver drugs and biologics to treat chronic diseases.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Eyepoint Pharmaceuticals Inc revenues increased 7% to $36.9M. Net loss increased 29% to $58.4M. Revenues reflect DEXYCU segment increase from $7M to $18.4M, YUTIQ segment increase of 22% to $17M, United States segment increase of 59% to $36M. Higher net loss reflects Research and Development Expense increase of 64% to $26.2M (expense), General and administrative increase of 19% to $20.7M (expense).

Equity composition

Common Stock $0.001 Par, 02/11, 60M auth., 20,741,392 issd. Insiders own 11.62%. 8/04 :49,804,381 shs issd @ $1.09each to pSiMedica Ltd on acquisition. 06/08, Name changed from pSivida Limited. 06/08, 1-for-40 reverse stock split.